Montreal’s Genizon Biosciences has closed $12.4 million in first tranche secured convertible debenture financing to increase its inventory of GeneMaps and disease drug targets. The syndicated financing includes HBM Bioventures, Biofund Management, and MVI Finance, as well as Genizon management, board members, employees and Illumina Inc